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Joao Pedro Ferreira, MD, PhD; Stuart J. Pocock, PhD; Peter Carson, MD; Inder Anand, MD; Wolfram Doehner, MD, PhD;  
Markus Haass, MD; Michel Komajda , MD; Alan Miller , MD; Steen Pehrson, MD; John R. Teerlink, MD;  
Sven Schnaidt, MSc; Cordula Zeller, Dipl Math; Janet M. Schnee, MD; Stefan D. Anker, MD, PhD;  
for the EMPEROR-Preserved Trial Study Group
BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart 
failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart 
failure events.
METHODS: We randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to 
double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 
months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and 
prespecified their analysis in individual and composite end points.
RESULTS: Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency 
or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, 
respectively]; hazard ratio, 0.77 [95% CI, 0.67–0.87]; P<0.0001). This benefit reached statistical significance at 18 days 
after randomization. Empagliflozin reduced the total number of heart failure hospitalizations that required intensive care 
(hazard ratio, 0.71 [95% CI, 0.52–0.96]; P=0.028) and the total number of all hospitalizations that required a vasopressor 
or positive inotropic drug (hazard ratio, 0.73 [95% CI, 0.55–0.97]; P=0.033). Compared with patients in the placebo group, 
fewer patients in the empagliflozin group reported outpatient intensification of diuretics (482 versus 610; hazard ratio, 0.76 
[95% CI, 0.67–0.86]; P<0.0001), and patients assigned to empagliflozin were 20% to 50% more likely to have a better New 
York Heart Association functional class, with significant effects at 12 weeks that were maintained for at least 2 years. The 
benefit on total heart failure hospitalizations was similar in patients with an ejection fraction of >40% to <50% and 50% to 
<60%, but was attenuated at higher ejection fractions.
CONCLUSIONS: In patients with heart failure with preserved ejection fraction, empagliflozin produced a meaningful, early, and 
sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.
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Heart failure is a progressive disorder marked by ongoing or episodic worsening of symptoms, leading to a deterioration of functional capacity 
and requiring intensification of treatment. Often, these 
episodes of clinical worsening can be managed in an 
outpatient setting, which can involve an office, clinic, 
emergency department, or urgent care setting. When 
severe or of rapid onset, worsening symptoms may 
require hospitalization, and if the patient becomes clini-
cally unstable, admission to intensive care. Therefore, the 
clinical progression of heart failure can manifest itself in 
a broad range of clinical settings. Although the primary 
end point of clinical trials typically focuses only on hospi-
talizations,1,2 these represent only a small proportion of a 
patient’s journey,3,4 and outpatient and inpatient worsen-
ing heart failure events can have similar adverse prog-
nostic implications.5–7
In clinical trials in type 2 diabetes or chronic kid-
ney disease, sodium-glucose cotransporter 2 (SGLT2) 
inhibitors reduced the risk of hospitalizations for heart 
failure.8–14 However, these trials did not evaluate the 
effect of these drugs on the broad spectrum of both 
inpatient and outpatient heart failure events. We and 
others have reported that in patients with heart fail-
ure with reduced ejection fraction, empagliflozin, dapa-
gliflozin, and sotagliflozin not only lowered the risk of 
hospitalization for heart failure, but also diminished the 
risk of outpatient events, including emergency or urgent 
care visits and outpatient intensification of diuretics for 
worsening heart failure.15–18 In this article, we report on 
the effect of empagliflozin on inpatient and outpatient 
worsening heart failure events in patients with heart 
failure and an ejection fraction >40%. Furthermore, 
because patients with heart failure with preserved 
ejection fraction (HFpEF) have comorbidities that can 
cause serious disability for reasons other than heart 
failure, we report on the effect of empagliflozin using 
more comprehensive definitions of death and hospital-
ization.19–23
METHODS
EMPEROR-Preserved (Empagliflozin Outcome Trial in 
Patients With Chronic Heart Failure With Preserved Ejection 
Fraction; URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT0305791) was a randomized, double-blind, parallel-group, 
placebo-controlled, event-driven study, whose design has been 
described previously.24,25 Ethics approval was obtained at each 
study site and informed consent was obtained from all study 
participants. Data will be made available on request in adher-
ence with transparency conventions in medical research and 
through requests to the corresponding author. The Executive 
Committee of the EMPEROR trials (Empagliflozin Outcome 
Trial in Patients With Chronic Heart Failure) has developed 
a comprehensive analysis plan and numerous prespecified 
analyses, which will be presented in future scientific meetings 
and publications. At a later time point, the full database will be 
made available in adherence with the transparency policy of the 
Clinical Perspective
What Is New?
• EMPEROR-Preserved (Empagliflozin Outcome Trial 
in Patients With Chronic Heart Failure With Preserved 
Ejection Fraction) showed that, in patients with heart 
failure and preserved ejection fraction, empagliflozin 
reduced the primary end point of cardiovascular death 
or hospitalization for heart failure, primarily related to 
a 29% lower risk of hospitalizations for heart failure.
• In the current analysis, we show that empagliflozin 
reduced the risk of severe hospitalizations, as reflected 
by admissions requiring the use of positive inotropic 
and vasopressor drugs and the need for intensive care.
• Empagliflozin also reduced the risk of outpatient 
worsening heart failure events, including need for 
urgent care visits, diuretic intensification, and unfa-
vorable changes in functional class.
What Are the Clinical Implications?
• Therapeutic options for patients with heart failure 
and preserved ejection fraction are limited; previous 
trials with various interventions have shown little or 
modest effects.
• The favorable effects of empagliflozin on inpatient and 
outpatient worsening heart failure events in patients 
with heart failure and preserved ejection fraction in 
EMPEROR-Preserved are similar to those reported 
with empagliflozin in patients with heart failure and 
reduced ejection fraction in EMPEROR-Reduced 
(Empagliflozin Outcome Trial in Patients With Chronic 
Heart Failure With Reduced Ejection Fraction).
Nonstandard Abbreviations and Acronyms
EMPEROR  Empagliflozin Outcome 
Trial in Patients With 
Chronic Heart Failure
EMPEROR-Preserved  Empagliflozin Outcome 
Trial in Patients With 
Chronic Heart Failure 
With Preserved Ejection 
Fraction
EMPEROR-Reduced  Empagliflozin Outcome 
Trial in Patients With 
Chronic Heart Failure 
With Reduced Ejection 
Fraction
HFpEF  heart failure with pre-
served ejection fraction
HR hazard ratio
NT-proBNP  N-terminal prohormone 
B-type natriuretic peptide
NYHA New York Heart Association
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sponsor (available at https://trials.boehringer-ingelheim.com/
transparency_policy.html).
Study Patients and Assessments
We enrolled men or women with chronic heart failure (New York 
Heart Association [NYHA] functional class II, III, or IV) with a 
left ventricular ejection fraction >40% who had elevated levels 
of NT-proBNP (N-terminal prohormone B-type natriuretic pep-
tide) >300 pg/mL; this threshold was tripled in patients with 
atrial fibrillation at baseline. Patients who fulfilled prespecified 
inclusion and exclusion criteria were randomized double-blind 
(in a 1:1 ratio) to receive placebo or empagliflozin 10 mg daily 
in addition to their usual therapy. After randomization, all appro-
priate treatments for heart failure or other medical conditions 
could be initiated or altered at the discretion of the physician of 
each patient. Patients were assessed at study visits for major 
outcomes, functional capacity related to heart failure, changes 
in the use of diuretics, vital signs, and biomarkers reflecting 
changes in the course of heart failure or the action of SGLT2 
inhibitors; these assessments took place every 2 to 6 months, 
depending on the metric and the duration of follow-up. All 
randomized patients were to be followed for prespecified out-
comes for the entire duration of the trial.
Trial End Points
In a manner similar to that followed for EMPEROR-Reduced 
(Empagliflozin Outcome Trial in Patients With Chronic Heart 
Failure With Reduced Ejection Fraction),15 we prospectively 
collected information on deaths, hospitalizations for any rea-
son, and emergency, urgent, and outpatient events that reflect 
worsening heart failure. Hospitalizations were classified as 
cardiovascular or noncardiovascular on the basis of the judg-
ment of the investigator, but hospitalizations for heart failure 
were prospectively adjudicated by a clinical event commit-
tee in a blinded manner using prespecified criteria. To qualify 
as an adjudicated heart failure hospitalization, patients were 
required to have meaningful worsening of their clinical status 
and intensification of treatment for heart failure. The duration 
of the in-hospital stay was at least 12 hours; if the patient had 
not received intravenous medications for heart failure, the mini-
mum stay of an adjudicated heart failure hospitalization was 
24 hours. Investigators documented the clinical course of each 
hospital admission on a dedicated form, including the prescrib-
ing of medications used to treat episodes of clinical decompen-
sation and the use of intensive care.
In addition to the adjudication and characterization of hos-
pitalizations for heart failure, at each scheduled study visit, 
patients were prospectively asked about interval events and 
about changes in the use of diuretics that were prescribed 
in response to worsening heart failure since the most recent 
visit. Events that were prospectively considered to reflect 
meaningful changes in clinical status included (1) worsening 
heart failure that required the use of an intravenous drug for 
heart failure in an emergency department or urgent care set-
ting; (2) intensification of daily doses of diuretics for worsening 
symptoms; and (3) changes in NYHA functional class. Events 
treated in an emergency department, urgent care setting, or 
during a hospital stay shorter than that required for an adjudi-
cated event were grouped together. Physicians were not pro-
vided any specific guidance as to the degree or duration of 
diuretic intensification that would qualify as representing a clin-
ically meaningful change. Ascertainment of these events and 
measures were prospectively collected in the case report form 
and their inclusion in analyses of individual and composite end 
points was prespecified before the blind of the trial was broken. 
Outpatient worsening heart failure events were not adjudicated.
The end points selected for inclusion in this article are 
similar to those that we analyzed for EMPEROR-Reduced,15 
and we prospectively planned to perform these analyses for 
EMPEROR-Preserved.
Statistical Analysis
For time-to-first-event analyses, differences between the pla-
cebo and empagliflozin groups were assessed using a Cox pro-
portional hazards model, with prespecified covariates of age, 
sex, geographical region, diabetes status at baseline, left ven-
tricular ejection fraction, and estimated glomerular filtration rate 
at baseline. To determine the time point when statistical signifi-
cance was reached and maintained for the first time, the same 
Cox regression models were fitted and sequentially censored at 
increasing number of days since randomization, yielding a con-
tinuous display of hazard ratios (HRs) with confidence bands. 
For the analysis of total (first and repeated) events, between-
group differences were assessed using a joint frailty model,26 
with cardiovascular death (for end points including heart failure 
events) or all-cause mortality (for end points including all-cause 
hospitalization) as competing risks and using the covariates 
that were used for the time-to-first-event analyses.
Odds ratios were calculated for the effect of empagliflozin 
versus placebo on NYHA class at prespecified study visits using 
ordinal logistic regression assuming partial proportional odds 
adjusting for baseline NYHA class and using the same covari-
ates as for the Cox regression models, without imputation for 
missing data. For the analysis of changes in vital signs and 
biomarkers, treatment effects were assessed on the basis of 
changes from baseline using a mixed model for repeated mea-
sures that included age and baseline estimated glomerular filtra-
tion rate and ejection fraction as linear covariates and baseline 
score by visit, visit by treatment, sex, region, individual last pro-
jected visit on the basis of dates of randomization and trial clo-
sure, and baseline diabetes status as fixed effects. The analysis 
of changes in N-terminal proBNP was performed on log-trans-
formed data. Because the outcome measures were highly cor-
related, no adjustment was made for multiplicity of comparisons.
RESULTS
A total of 5988 patients were randomly assigned to pla-
cebo (n=2991) or to empagliflozin (n=2997). As previ-
ously reported,25 the 2 groups had clinical features typi-
cal of patients with HFpEF and they were well-balanced 
with respect to baseline characteristics.
Effect on Combined Risk of Death or 
Hospitalization
There were 662 patients who died for any reason or were 
hospitalized for heart failure in the placebo group and 
581 such patients in the empagliflozin group, reflecting 
ORIGINAL RESEARCH 
ARTICLE
Circulation. 2021;144:1284–1294. DOI: 10.1161/CIRCULATIONAHA.121.056824 October 19, 2021 1287
Packer et al Empagliflozin and HF in HFpEF
a 15% lower risk with empagliflozin compared with pla-
cebo (HR, 0.85 [95% CI, 0.76–0.95]; P=0.005; Table 1). 
There were 967 patients who died for any reason or 
were hospitalized for a cardiovascular reason in the pla-
cebo group and 888 such patients in the empagliflozin 
group, reflecting a 11% lower risk with empagliflozin 
than placebo (HR, 0.89 [95% CI, 0.81–0.98]; P=0.014). 
There were 1431 patients who died or were hospitalized 
for any reason in the placebo group and 1356 such pa-
tients in the empagliflozin group, reflecting an 8% lower 
risk with empagliflozin than placebo (HR, 0.92 [95% CI, 
0.85–0.99]; P=0.025; Table 1).
Effect of Empagliflozin on Hospitalizations
Compared with the placebo group, patients in the empa-
gliflozin group had fewer total (first and recurrent) hos-
pitalizations for heart failure (407 versus 541; HR, 0.73 
[95% CI, 0.61–0.88]; P=0.0009) and fewer total (first 
and recurrent) hospitalizations for a cardiovascular rea-
son (1145 versus 1333; HR, 0.84 [95% CI, 0.74–0.95]; 
P=0.005). Total (first and recurrent) hospitalizations for 
any reason were not significantly different in the 2 treat-
ment groups (2566 versus 2769; empagliflozin versus 
placebo, respectively; HR, 0.93 [95% CI, 0.85–1.01]; 
P=0.10; Table 1). However, among these, empagliflozin 
reduced the total number of hospitalizations requir-
ing intravenous diuretics by 33% (HR, 0.67 [95% CI, 
0.57–0.79]; P<0.0001) and the total number of hospi-
talizations requiring intravenous vasopressor or positive 
inotropic agents by 27% (HR, 0.73 [95% CI, 0.55–0.97]; 
P=0.03; Figure 1).
The effect of empagliflozin on total hospitalizations 
for heart failure is described in Table 2. Compared with 
patients in the placebo group, fewer patients in the empa-
gliflozin group were hospitalized for heart failure once 
(181 versus 243), hospitalized for heart failure twice (49 
versus 67), and hospitalized for heart failure 3 or more 
times (29 versus 42). The effect of empagliflozin on 
total (first and recurrent) hospitalizations for heart failure 
was consistent in most of the prespecified subgroups. 
For this end point, we observed a nominally significant 
interaction between treatment and the baseline use 
of mineralocorticoid receptor antagonists (interaction 
P=0.038) as well as an interaction between treatment 
and ejection fraction (P trend=0.008), with an attenu-
ated response in patients with an ejection fraction ≥60% 
(Figure I in the Data Supplement). When the analysis of 
hospitalizations was broadened to total (first and recur-
rent) cardiovascular hospitalizations, only the interaction 
between treatment and ejection fraction was still appar-
ent (P trend=0.02), again with an attenuated response in 
patients with an ejection fraction ≥60% (Figure II in the 
Data Supplement).
Empagliflozin also reduced the severity of heart failure 
admissions and the frequency of use of a broad range of 
interventions used for the management of decompen-
sated heart failure. Empagliflozin prolonged the time to 
the first heart failure hospitalization that required intensive 
care and decreased the total number of such heart fail-
ure admissions (HR, 0.71 [95% CI, 0.52–0.96]; P=0.03; 
Table 1 and Figure 2). When compared with the placebo 
group, the empagliflozin group experienced fewer total 
hospitalizations for heart failure that required only oral or 
intravenous diuretics (297 versus 366), fewer hospital-
izations for heart failure that required intravenous vasodi-
lators but no vasopressor or positive inotropic agents (32 
versus 65), and fewer admissions for heart failure that 
required a vasopressor or positive inotropic agent (45 
versus 72; Table 2). When considering all hospitalizations 
for heart failure, the 2 groups were similar with respect 
to the mean duration of each admission for heart failure 
(10.8 [95% CI, 9.6–12.0] and 11.5 [95% CI, 10.0–12.9] 
for placebo versus empagliflozin, respectively; P=0.50).
Effect of Empagliflozin on Worsening Heart 
Failure Events Other Than Hospitalizations
Patients in the empagliflozin group experienced fewer 
emergency or urgent care visits for worsening heart fail-
ure (298 events in the placebo group and 174 in the 
empagliflozin group; HR, 0.55 [95% CI, 0.43–0.69]; 
P<0.0001). When a worsening heart failure event is de-
fined as cardiovascular death, hospitalization for heart 
failure, or an emergency or urgent heart failure visit re-
quiring intravenous treatment, there were 546 events in 
the placebo group and 432 events in the empagliflozin 
group, reflecting a 23% lower risk of a worsening heart 
failure event with empagliflozin (HR, 0.77 [95% CI, 0.67–
0.87]; P<0.0001; Table 1). The benefit of empagliflozin 
on this end point first reached statistical significance at 
18 days after randomization and maintained significance 
thereafter (Figure 3).
Compared with placebo, fewer patients in the empa-
gliflozin group reported outpatient intensification of diuret-
ics since the prior study visit (482 versus 610) and there 
were fewer total study visits that reported interval outpa-
tient diuretic intensification in the empagliflozin group (626 
versus 838; Tables 1 and 2). Conversely, the empagliflozin 
group had more patients (424 versus 358) and more 
study visits (519 versus 445) where the dose of diuret-
ics was reported to have been reduced. Empagliflozin pro-
longed the time to the first study visit that reported interval 
outpatient diuretic intensification (HR, 0.76 [95% CI, 0.67-
0.86]; P<0.0001, and the drug reduced the total number 
of study visits that reported interval outpatient intensifica-
tion of diuretics since the prior visit (HR, 0.73 [95% CI, 
0.65–0.82]; P<0.0001; Table 1 and Figure 4).
In general, at each prespecified study visit, patients 
in the empagliflozin group were at 20% to 50% greater 
odds of having a less severe NYHA functional class than 
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Table 1. Major Outcomes and Worsening Heart Failure Events
Outcomes and events
Placebo (n=2991) Empagliflozin (n=2997)
Hazard ratio 







All-cause and cardiovascular outcomes
 Time to all-cause mortality or hospitalization for heart failure 662 (22.1) 11.2 581 (19.4) 9.6 0.85 (0.76–0.95) 0.005
 Time to all-cause mortality or cardiovascular hospitalization 967 (32.3) 18.1 888 (29.6) 16.1 0.89 (0.81–0.98) 0.014
 Time to all-cause mortality or hospitalization for any reason 1431 (47.8) 31.2 1356 (45.2) 28.6 0.92 (0.85–0.99) 0.025
 Time to first hospitalization for cardiovascular reason 765 (25.6) 14.3 669 (22.3) 12.2 0.85 (0.77–0.94) 0.002
 Time to first hospitalization for any reason 1340 (44.8) 29.2 1271 (42.4) 26.8 0.92 (0.85–0.99) 0.032
 Total (first and recurrent) number of cardiovascular hospitalizations 1333  1145  0.84 (0.74–0.95) 0.005
 Total (first and recurrent) number of hospitalizations for any reason 2769  2566  0.93 (0.85–1.01) 0.101
 Total hospitalizations requiring intravenous diuretics 727  516  0.67 (0.57–0.79) <0.0001
  Total hospitalizations requiring intravenous vasopressors or 
positive inotropic drugs
140  102  0.73 (0.55–0.97) 0.033
Worsening heart failure events
 Worsening heart failure requiring hospitalization
  Time to first adjudicated hospitalization for heart failure 352 (11.8) 6.0 259 (8.6) 4.3 0.71 (0.60–0.83) <0.0001
   Time to first adjudicated hospitalization for heart failure requir-
ing intravenous vasopressors or positive inotropic drugs
54 (1.8) 0.9 37 (1.2) 0.6 0.67 (0.44–1.02) 0.065
   Time to first adjudicated hospitalization for heart failure requir-
ing cardiac care unit/intensive care unit care
94 (3.1) 1.5 68 (2.3) 1.1 0.71 (0.52–0.97) 0.032
   Total (first and recurrent) number of adjudicated hospitaliza-
tions for heart failure
541  407  0.73 (0.61–0.88) 0.0009
   Total adjudicated hospitalizations for heart failure requiring 
intravenous vasopressors or positive inotropic drugs
72  45  0.62 (0.41–0.92) 0.019
   Total adjudicated hospitalizations for heart failure requiring 
cardiac care unit/intensive care unit care
117  86  0.71 (0.52–0.96) 0.028
   Time to first investigator-identified hospitalization for heart 
failure
485 (16.2) 8.5 362 (12.1) 6.1 0.72 (0.63–0.82) <0.0001
 Worsening heart failure requiring emergency or urgent care
   Time to first emergency or urgent care visit for worsening 
heart failure requiring intravenous therapy
215 (7.2) 3.5 136 (4.5) 2.2 0.61 (0.50–0.76) <0.0001
   Time to adjudicated hospitalization for heart failure or emer-
gency or urgent care for heart failure requiring intravenous 
therapy
393 (13.1) 6.7 280 (9.3) 4.7 0.69 (0.59–0.80) <0.0001
   Time to cardiovascular mortality, adjudicated hospitalization 
for heart failure, or emergency or urgent care for heart failure 
requiring intravenous therapy
546 (18.3) 9.3 432 (14.4) 7.2 0.77 (0.67–0.87) <0.0001
 Worsening heart failure requiring outpatient intensification of diuretics
   Time to first study visit that reported interval outpatient inten-
sification of diuretics
610 (20.4) 11.1 482 (16.1) 8.5 0.76 (0.67–0.86) <0.0001
   Total (first and recurrent) study visits that reported interval 
outpatient intensification of diuretics
838  626  0.73 (0.65–0.82) <0.0001
   Time to adjudicated hospitalization for heart failure, emer-
gency or urgent care for heart failure requiring intravenous 
therapy, or interval outpatient intensification of diuretics
813 (27.2) 15.5 635 (21.2) 11.5 0.74 (0.67–0.82) <0.0001
To avoid double-counting, the total number of emergency or urgent care visits and hospitalizations for heart failure were not summated, because many emergency 
or urgent care cases were followed within 1 to 2 days by admission to a hospital for the same clinical event. All events that are not designated as being adjudicated 
were investigator-identified. For time-to-first-event analyses, differences between the placebo and empagliflozin groups were assessed using a Cox proportional 
hazards model, adjusting for covariates of age, sex, geographic region, diabetes status at baseline, left ventricular ejection fraction, and estimated glomerular filtration 
rate at baseline. For the analysis of total (first and repeated) events, between-group differences were assessed using a joint frailty model, with cardiovascular death 
(for end points including heart failure events) or all-cause mortality (for end points including all-cause hospitalization) as competing risks and using the covariates that 
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difference was nearly significant at week 4 (P=0.06) 
and was statistically significant at all time points from 12 
weeks through 148 weeks after randomization (Table 3).
Serial changes in laboratory tests and vital signs are 
shown in Figures III through VII in the Data Supplement. 
Treatment with empagliflozin was accompanied by small 
decreases in NT-proBNP after 4 weeks and the effect 
increased in magnitude over time. Empagliflozin pro-
duced significant increases in hematocrit and decreases 
in uric acid, which were apparent as early as 4 weeks 
after randomization and were maintained for >24 
months. Patients treated with empagliflozin experienced 
Figure 1. Total (first and recurrent) 
hospitalizations for any reason that 
required intravenous vasopressors or 
positive inotropic agents. 
Shown are mean cumulative function 
curves for placebo (shown in red) and for 
empagliflozin (shown in blue). HR indicates 
hazard ratio.
Table 2. Occurrence of Worsening Heart Failure Events
Heart failure events Placebo Empagliflozin
Adjudicated hospitalizations for heart failure
 Patients hospitalized once 243 181
 Patients hospitalized twice 67 49
 Patients hospitalized ≥3 times 42 29
Total (first and recurrent) adjudicated hospitalizations for heart failure
 Number of hospitalizations requiring only oral or intravenous diuretics 366 297
 Number of hospitalizations requiring intravenous vasodilators 65 32
 Number of hospitalizations requiring intravenous vasopressors or positive inotropic drugs 72 45
Total (first and recurrent) emergency or urgent care visits for heart failure requiring intravenous therapy
 Patients who required emergency or urgent care once 165 110
 Patients who required emergency or urgent care twice 31 20
 Patients who required emergency or urgent care ≥3 times 19 6
Outpatient changes in diuretic dose since previous study visit
 Number of patients who had diuretics intensified since previous study visit 610 482
 Total number of study visits that reported that the dose of diuretics had been intensified since previous study visit 838 626
 Number of patients who had reduction in the dose of diuretics since previous study visit 358 424
 Total number of study visits that reported that the dose of diuretics had been reduced since previous study visit 445 519
Categories are ordered according to severity of intervention, with each category including less intensive but excluding more intensive interventions 
(ie, use of intravenous vasodilators includes the use of diuretics but excludes the use of intravenous positive inotropic drugs or vasopressors). A total 
of 38 patients in the placebo group and 32 in the empagliflozin group did not have complete information on the use of drug or nondrug interventions 
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an early and sustained decrease in body weight and sys-
tolic blood pressure, which averaged somewhat greater 
than 1 kg and 2 mm Hg, respectively.
DISCUSSION
As previously reported, in EMPEROR-Preserved, empa-
gliflozin reduced the risk of cardiovascular death or hos-
pitalization for heart failure by 21% (P<0.001), an effect 
that was related primarily to reduction in hospitalizations 
for heart failure.25 We show that when the analysis is 
expanded to include all deaths and all hospitalizations 
regardless of attribution, the effect of empagliflozin on 
morbidity and mortality remained statistically significant 
(P=0.025). However, as expected, the magnitude of the 
effect on hospitalization diminished when the focus of 
the analysis broadened beyond heart failure events, de-
creasing from a 27% risk reduction for total heart failure 
hospitalizations to 16% risk reduction for total cardio-
vascular hospitalizations to 7% risk reduction for total 
hospitalizations for any reason. This decline is expect-
ed whenever hospitalizations that are not particularly 
Figure 2. Total (first and recurrent) 
adjudicated heart failure 
hospitalizations requiring admission 
to cardiac care unit or intensive care 
unit in the placebo and empagliflozin 
groups.
Shown are mean cumulative function 
curves for placebo (shown in red) and for 
empagliflozin (shown in blue). HR indicates 
hazard ratio.
Figure 3. Time of first statistical 
significance in time-to-first-event 
analysis of cardiovascular death, 
hospitalization for heart failure, or 
emergency or urgent heart failure 
visit requiring intravenous treatment 
for worsening heart failure.
To determine the time point when 
statistical significance was reached 
and maintained for the first time, Cox 
regression models were fitted and 
sequentially censored at increasing 
number of days since randomization, 
yielding a continuous display of hazard 
ratios with confidence bands.
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influenced by a treatment are added in a stepwise man-
ner to the analysis of events in a trial of patients with 
HFpEF, in whom only 46% of the hospital admissions 
are related to a cardiovascular reason and only 18% are 
related to worsening heart failure.
Empagliflozin reduced the risk of hospitalization for 
heart failure, whether the analysis was broadened to 
investigator-identified events or focused on adjudicated 
events. The hospitalizations that were prevented by treat-
ment with empagliflozin involved admissions that were 
treated only with oral or intravenous diuretics as well as 
hospitalizations that required therapy with intravenous 
vasopressors or positive inotropic agents or that neces-
sitated intensive care. These benefits of SGLT2 inhibi-
tion were seen in time-to-first-event analyses and in the 
analysis of total (first and recurrent) events; the number 
of patients who were hospitalized once or multiple times 
was fewer in the empagliflozin group than in the placebo 
group. Empagliflozin reduced the total number of hos-
pitalizations for heart failure that involved admission to 
intensive care by 29% (HR, 0.71 [95% CI, 0.52–0.96]) 
and the total number of admissions for any reason that 
required intravenous vasopressors or positive inotropic 
drugs by 27% (HR, 0.73 [95% CI, 0.55–0.97]). The 
lower risk of hospital admissions did not result in a longer 
length of stay when patients in the empagliflozin group 
were hospitalized for heart failure.
In addition to these inpatient events, treatment with 
empagliflozin had an important effect to mitigate wors-
ening heart failure events in the outpatient setting. 
There were fewer emergency or urgent care visits for 
worsening heart failure in the empagliflozin group than 
in the placebo group. SGLT2 inhibition reduced the 
number of study visits that reported diuretic intensifi-
cation for worsening heart failure by 25%, and at the 
same time, empagliflozin led to a 17% increase in the 
number of study visits that reported a decrease in dose 
of diuretics. Moreover, patients in the empagliflozin 
group had a 20% to 50% higher odds of having a better 
NYHA functional class; these benefits were apparent 
early in treatment and were sustained for the duration 
of double-blind therapy. An early symptom effect is 
concordant with our finding on clinical events; that is, 
when worsening heart failure was defined in a manner 
similar to the primary end point of DAPA-HF (Study to 
Figure 4. Total number of 
outpatient visits reporting interval 
intensification of diuretics for 
worsening heart failure.
Shown are mean cumulative function 
curves for placebo (shown in red) and for 
empagliflozin (shown in blue). HR indicates 
hazard ratio.
Table 3. Odds Ratios (Empagliflozin: Placebo) for a Less 
Severe New York Heart Association Functional Class at 







Odds ratio (95% CI);  
P value
4 2945 2967 1.17 (0.99–1.37); 0.063
12 2896 2924 1.23 (1.07–1.41); 0.004
32 2780 2792 1.30 (1.14–1.49); <0.0001
52 2683 2689 1.37 (1.20–1.57); <0.0001
76 2423 2390 1.43 (1.24–1.64); <0.0001
100 1857 1833 1.21 (1.04–1.41); 0.016
124 1306 1319 1.33 (1.11–1.60); 0.002
148 778 779 1.48 (1.17–1.88); 0.001
Shown are odds ratios, 95% CIs, and P values for each study visit. No im-
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Evaluate the Effect of Dapagliflozin on the Incidence 
of Worsening Heart Failure or Cardiovascular Death in 
Patients With Chronic Heart Failure; eg, cardiovascu-
lar death, hospitalization for heart failure, or an emer-
gency or urgent heart failure visit requiring intravenous 
treatment),27 a benefit of empagliflozin was apparent 
(HR, 0.77 [95% CI, 0.67–0.87]) and first reached sta-
tistical significance at 18 days after randomization and 
remained significant for the duration of follow-up. This 
finding of early benefits is similar to that which we and 
others have reported with SGLT2 inhibitors in patients 
with heart failure with reduced ejection fraction.15,27
The effects of empagliflozin on inpatient and outpa-
tient worsening heart failure events was largely con-
sistent across our predefined subgroups. We noted a 
possible influence of concomitant treatment with min-
eralocorticoid receptor antagonists in an analysis of the 
effect of empagliflozin on total heart failure hospitaliza-
tions, but this interaction was no longer apparent when 
we broadened the analysis to all cardiovascular hospi-
talizations. In contrast, ejection fraction influenced the 
magnitude of the effect of empagliflozin when the analy-
sis focused on total hospitalizations for heart failure (P 
trend=0.008) or on all cardiovascular hospitalizations (P 
trend=0.02). These findings are concordant with our yet-
to-be-published observations that the effect of empa-
gliflozin to reduce the risk of heart failure hospitalization 
is similar in magnitude across a broad range of ejection 
fractions ranging from <25% to <65% but is attenuated 
in patients with an ejection fraction of 65% or greater. 
Further characterization of patients with heart failure and 
high-normal ejection fractions is warranted.
The mechanisms by which empagliflozin reduces inpa-
tient and outpatient worsening heart failure events are 
not well understood. Although the early benefits of empa-
gliflozin to prevent clinical deterioration may suggest the 
possibility of a natriuretic effect,28 the magnitude of such 
an action is typically modest and short-lived.29–31 Conven-
tional diuretics typically produce immediate declines in 
natriuretic peptides, generally without a change in hema-
tocrit. In contrast, the early effect of empagliflozin on 
natriuretic peptides was very small in our trial, and hema-
tocrit increased (presumably as a result of erythrocyto-
sis32), a pattern similar to that seen with empagliflozin 
in patients with heart failure with reduced ejection frac-
tion.15 Many patients with HFpEF are hypertensive, and 
systolic blood pressure decreased modestly with empa-
gliflozin. Sacubitril/valsartan produces greater decreases 
in blood pressure, but more modest decreases in the risk 
of hospitalization and emergency or urgent care visits.33–35 
Obesity can play an important role in HFpEF,36,37 but the 
decline in body weight with empagliflozin was too small 
to mitigate the influence of adiposity. Inflammation and 
oxidative stress have been implicated in the pathogene-
sis of HFpEF,38,39 and empagliflozin produced meaningful 
and sustained decreases in uric acid, a marker of oxida-
tive stress.40 SGLT2 inhibitors have been shown to ame-
liorate inflammation and oxidative stress in experimental 
HFpEF.41,42 The importance of these mechanisms in the 
clinical setting remain to be fully explored.
The findings of the present study should be inter-
preted in light of its strengths and limitations. This trial 
is the largest randomized double-blind controlled trial 
in patients with HFpEF, and we prospectively collected 
information on inpatient and outpatient worsening heart 
failure events; the outpatient clinical course of these 
patients has not been well-characterized to date. How-
ever, noninvasive assessment of cardiac structure and 
function were not standardized or interpreted in a central 
laboratory. Thus, we were not able to explore the hetero-
geneity of this patient population, and our measurements 
of ejection fraction are subject to the variability typically 
seen in clinical practice.
In conclusion, in patients with HFpEF, SGLT2 inhibi-
tion with empagliflozin produced a meaningful, early, and 
sustained reduction in the risk and severity of a broad 
range of inpatient and outpatient worsening heart failure 
events. These benefits included a decrease in the need 
for hospitalizations requiring aggressive therapy, a dimi-
nution of worsening events requiring intensification of 
diuretics, and an increased likelihood of functional class 
improvement, effects that were maintained for >2 years 
of double-blind treatment.
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